Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX) in the last three months. In the table below ...

Pinnacle Associates Ltd. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 44.4% in the ...

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

As Vertex Pharmaceuticals Inc. heads toward the end of 2024, the Boston drugmaker is gearing up for two potential drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) and keeping the price target at $555.00. Mohit Bansal has given his Buy rating ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $484.94, indicating a +0.67% change from the previous session's end. This move lagged the S&P 500's daily gain of 0.77%. On the other ...

(Reuters) - Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects ...